Results

Total Results: over 10,000 records

Showing results for "limitations".

  1. www.monahrq.ahrq.gov/sites/default/files/wysiwyg/pqmp/measures/acute/chipra-228-fullreport.pdf
    February 01, 2018 - Limitations of the Measure Describe any limitations of the measure related to the attributes included … the measure should be selected for use, taking into account a balance among desirable attributes and limitationsLimitations of the Measure Section 13.
  2. www.cahps.ahrq.gov/sites/default/files/wysiwyg/pqmp/measures/acute/chipra-228-fullreport.pdf
    February 01, 2018 - Limitations of the Measure Describe any limitations of the measure related to the attributes included … the measure should be selected for use, taking into account a balance among desirable attributes and limitationsLimitations of the Measure Section 13.
  3. ce.effectivehealthcare.ahrq.gov/sites/default/files/wysiwyg/pqmp/measures/acute/chipra-228-fullreport.pdf
    February 01, 2018 - Limitations of the Measure Describe any limitations of the measure related to the attributes included … the measure should be selected for use, taking into account a balance among desirable attributes and limitationsLimitations of the Measure Section 13.
  4. effectivehealthcare.ahrq.gov/sites/default/files/related_files/childhood-cancer-disposition-comments.pdf
    February 16, 2022 - and “Discussion, Summary of Findings). 9 Peer Reviewer #1 Discussion and Conclusions in the limitations … comment. 18 Peer Reviewer #2 Discussion and Conclusions I think that authors very clearly address limitations … The paragraph itself clearly describes the Strengths and Limitations of our literature review approach … . 45 Peer Reviewer #4 Discussion and Conclusions Implications of discussions are adequate and limitations
  5. effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/childhood-cancer-disposition-comments.pdf
    February 16, 2022 - and “Discussion, Summary of Findings). 9 Peer Reviewer #1 Discussion and Conclusions in the limitations … comment. 18 Peer Reviewer #2 Discussion and Conclusions I think that authors very clearly address limitations … The paragraph itself clearly describes the Strengths and Limitations of our literature review approach … . 45 Peer Reviewer #4 Discussion and Conclusions Implications of discussions are adequate and limitations
  6. www.ahrq.gov/sites/default/files/wysiwyg/pqmp/measures/acute/chipra-228-fullreport.pdf
    February 01, 2018 - Limitations of the Measure Describe any limitations of the measure related to the attributes included … the measure should be selected for use, taking into account a balance among desirable attributes and limitationsLimitations of the Measure Section 13.
  7. effectivehealthcare.ahrq.gov/sites/default/files/related_files/high-cholestorol-medications_disposition-comments.pdf
    March 10, 2010 - described in the report should be very carefully written to reflect this narrow focus and the resulting limitations … Each of these limitations is significant in that they relate to treatment decisions that physicians … We also think that the report needs to clearly explain the limitations of any conclusions that should … However, because of limitations of space, papers seldom describe full study methods.
  8. effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/high-cholestorol-medications_disposition-comments.pdf
    March 10, 2010 - described in the report should be very carefully written to reflect this narrow focus and the resulting limitations … Each of these limitations is significant in that they relate to treatment decisions that physicians … We also think that the report needs to clearly explain the limitations of any conclusions that should … However, because of limitations of space, papers seldom describe full study methods.
  9. www.cahps.ahrq.gov/sites/default/files/wysiwyg/pqmp/measures/perinatal/chipra-0082-fullreport.pdf
    March 01, 2016 - Limitations of the Measure Describe any limitations of the measure related to the attributes included … the measure should be selected for use, taking into account a balance among desirable attributes and limitationsLimitations of the Measure Section 13.
  10. www.healthcare411.ahrq.gov/sites/default/files/wysiwyg/pqmp/measures/perinatal/chipra-0082-fullreport.pdf
    March 01, 2016 - Limitations of the Measure Describe any limitations of the measure related to the attributes included … the measure should be selected for use, taking into account a balance among desirable attributes and limitationsLimitations of the Measure Section 13.
  11. www.innovations.ahrq.gov/sites/default/files/wysiwyg/pqmp/measures/perinatal/chipra-0082-fullreport.pdf
    March 01, 2016 - Limitations of the Measure Describe any limitations of the measure related to the attributes included … the measure should be selected for use, taking into account a balance among desirable attributes and limitationsLimitations of the Measure Section 13.
  12. www.talkingquality.ahrq.gov/sites/default/files/wysiwyg/pqmp/measures/perinatal/chipra-0082-fullreport.pdf
    March 01, 2016 - Limitations of the Measure Describe any limitations of the measure related to the attributes included … the measure should be selected for use, taking into account a balance among desirable attributes and limitationsLimitations of the Measure Section 13.
  13. www.qualitymeasures.ahrq.gov/sites/default/files/wysiwyg/pqmp/measures/perinatal/chipra-0082-fullreport.pdf
    March 01, 2016 - Limitations of the Measure Describe any limitations of the measure related to the attributes included … the measure should be selected for use, taking into account a balance among desirable attributes and limitationsLimitations of the Measure Section 13.
  14. www.monahrq.ahrq.gov/sites/default/files/wysiwyg/pqmp/measures/perinatal/chipra-0082-fullreport.pdf
    March 01, 2016 - Limitations of the Measure Describe any limitations of the measure related to the attributes included … the measure should be selected for use, taking into account a balance among desirable attributes and limitationsLimitations of the Measure Section 13.
  15. ce.effectivehealthcare.ahrq.gov/sites/default/files/wysiwyg/pqmp/measures/perinatal/chipra-0082-fullreport.pdf
    March 01, 2016 - Limitations of the Measure Describe any limitations of the measure related to the attributes included … the measure should be selected for use, taking into account a balance among desirable attributes and limitationsLimitations of the Measure Section 13.
  16. www.ahrq.gov/sites/default/files/wysiwyg/pqmp/measures/perinatal/chipra-0082-fullreport.pdf
    March 01, 2016 - Limitations of the Measure Describe any limitations of the measure related to the attributes included … the measure should be selected for use, taking into account a balance among desirable attributes and limitationsLimitations of the Measure Section 13.
  17. Insomnia Executive (pdf file)

    effectivehealthcare.ahrq.gov/sites/default/files/related_files/insomnia_executive.pdf
    December 01, 2015 - Methodological limitations have prevented conclusive evidence synthesis for these treatments.14-23 … of risk of bias across domains and confidence that the results were believable given the study’s limitations … Study limitations included possible unmeasured or unknown confounders. … Limitations Current evidence has several limitations. … These limitations further complicate the translation of reported changes 23 in sleep or global
  18. Insomnia Executive (pdf file)

    effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/insomnia_executive.pdf
    December 01, 2015 - Methodological limitations have prevented conclusive evidence synthesis for these treatments.14-23 … of risk of bias across domains and confidence that the results were believable given the study’s limitations … Study limitations included possible unmeasured or unknown confounders. … Limitations Current evidence has several limitations. … These limitations further complicate the translation of reported changes 23 in sleep or global
  19. Topic-Brief3-Sud (pdf file)

    effectivehealthcare.ahrq.gov/sites/default/files/related_files/topic-brief3-SUD.pdf
    April 01, 2021 - estimated prevalence of 20.4 percent in U.S. adults, with 8.0 percent reporting high impact (resulting in limitations … Methodological limitations included baseline differences between groups and failure to control for confounding
  20. Topic-Brief3-Sud (pdf file)

    effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/topic-brief3-SUD.pdf
    April 01, 2021 - estimated prevalence of 20.4 percent in U.S. adults, with 8.0 percent reporting high impact (resulting in limitations … Methodological limitations included baseline differences between groups and failure to control for confounding